Article
Pharmacology & Pharmacy
Manuela Carvalheiro, Margarida Ferreira-Silva, Denys Holovanchuk, H. Susana Marinho, Joao Nuno Moreira, Helena Soares, M. Luisa Corvo, Maria Eugenia M. Cruz
Summary: This study evaluated the ability of antagonist G to improve the targeting and internalization of liposomal formulations to small cell lung carcinoma (SCLC) cell lines. The results showed that covalent attachment of antagonist G increased cellular association and internalization of liposomes via receptor-mediated and clathrin-dependent endocytosis. Biodistribution studies in mice demonstrated preferential lung accumulation of antagonist G-targeted liposomes, indicating their potential as delivery vectors for SCLC treatment.
INTERNATIONAL JOURNAL OF PHARMACEUTICS
(2022)
Article
Biotechnology & Applied Microbiology
Andrew D. Baik, Philip Calafati, Xiaoli Zhang, Nina A. Aaron, Antonia Mehra, Sven Moller-Tank, Lawrence Miloscio, Maria Praggastis, Nicholas Giovannone, Cheryl Pan, Yajun Tang, Susannah Bridges, Alejo Mujica, Peter Barbounis, Jean Yanolatos, Nicholas Gale, Ning Li, Christos A. Kyratsous, Christopher J. Schoenherr, Andrew J. Murphy, Aris N. Economides, Katherine D. Cygnar
Summary: Targeted ERT, utilizing antibody-enzyme fusion proteins to target specific cell types, is shown to be superior in treating lysosomal diseases, such as Pompe disease, compared to traditional ERT methods.
Review
Medicine, Research & Experimental
Zhencong Ye, Yongmei Huang, Jianhao Ke, Xiao Zhu, Shuilong Leng, Hui Luo
Summary: Non-small cell lung cancer (NSCLC) is the most common and deadly malignancy of lung cancer; chemotherapy is gradually withdrawn from the stage of history due to its obvious side effects; researchers are now focusing on targeted drugs for the treatment.
BIOMEDICINE & PHARMACOTHERAPY
(2021)
Review
Biochemistry & Molecular Biology
Xueli Tian, Tingxuan Gu, Mee-Hyun Lee, Zigang Dong
Summary: Lung cancer is the most deadly cancer worldwide, with non-small cell lung cancer (NSCLC) being the main type and EGFR as a key driver gene. Despite the effectiveness of EGFR-tyrosine kinase inhibitors in targeted therapy, acquired resistance remains a significant challenge, prompting the exploration of combination treatment options.
BIOCHIMICA ET BIOPHYSICA ACTA-REVIEWS ON CANCER
(2022)
Review
Pharmacology & Pharmacy
Yanxia Xiao, Pu Liu, Jie Wei, Xin Zhang, Jun Guo, Yajun Lin
Summary: The high morbidity and mortality of non-small cell lung cancer pose significant health threats. However, with the identification of carcinogenic drivers and the use of targeted drugs, the prognosis for patients has greatly improved. Nonetheless, the unknown carcinogenic drivers and the issue of drug resistance in targeting therapy still hinder effective treatment. This review discusses the mechanisms of targeted-drug resistance and newly identified targets, highlighting the importance of research in driving individualized treatment for non-small cell lung cancer.
FRONTIERS IN PHARMACOLOGY
(2023)
Review
Oncology
Yichi Zhang, Elizabeth Holland, Anna Dinh, Duc Au, Lichun Sun
Summary: Small cell lung cancer (SCLC) is an aggressive form of lung cancer that is often treated with chemotherapy, radiation therapy, and surgery. Recent advances in pharmacological research have identified bombesin and bombesin receptors as important targets for the treatment of SCLC. Chemotherapy drugs conjugated to bombesin or bombesin-like peptides have shown improved therapeutic efficacy and specificity, as well as enhanced cytotoxicity towards drug-resistant SCLC cells. Bombesin-radioisotope conjugates can also be used for early detection of SCLC and targeted radiotherapy. Further studies are needed to explore the potential applications of bombesin conjugates in the diagnosis and management of SCLC.
AMERICAN JOURNAL OF CANCER RESEARCH
(2022)
Review
Biochemistry & Molecular Biology
Nicholas McNamee, Ines Pires da Silva, Adnan Nagrial, Bo Gao
Summary: Small-cell lung cancer (SCLC) is an aggressive disease with limited treatment options and poor survival rates. While there have been significant advancements in the treatment of non-small cell lung cancer (NSCLC), SCLC has not seen the same level of progress. This is due, in part, to the complex and heterogeneous nature of SCLC tumors. This review explores the current treatment paradigm of SCLC, recent advances in immunotherapy, challenges in identifying predictive biomarkers, and potential future directions in SCLC treatment research.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
(2023)
Review
Neurosciences
Lang He, Zhao Chen, Linliu Peng, Beisha Tang, Hong Jiang
Summary: Polyglutamine diseases are a group of neurodegenerative disorders for which there is currently no effective therapy. Intensive research is being conducted on the pathogenesis and potential treatment strategies. Stem cells offer a valuable resource for studying the mechanisms of these diseases and for potential treatment through cell transplantation.
EXPERIMENTAL NEUROLOGY
(2021)
Article
Pharmacology & Pharmacy
Fang Li, Chengqiong Mao, Stacy Yeh, Yao Sun, Junbo Xin, Qin Shi, Xin Ming
Summary: This study demonstrates that the anti-MRP1 antibody (Mab)-IR700 conjugate shows higher cellular delivery in multidrug resistant SCLC cells, leading to a stronger photokilling effect and tumor suppression.
INTERNATIONAL JOURNAL OF PHARMACEUTICS
(2021)
Article
Chemistry, Multidisciplinary
Alba Garcia-Fernandez, Monica Sancho, Viviana Bisbal, Pedro Amoros, Maria D. Marcos, Mar Orzaez, Felix Sancenon, Ramon Martinez-Manez
Summary: The new mesoporous silica nanoparticles-based nanodevice can target lung inflammation and reduce cytokine levels, showing promising anti-inflammatory effects in an ALI mouse model, which could be used for improving ALI treatment methods.
JOURNAL OF CONTROLLED RELEASE
(2021)
Article
Medicine, Research & Experimental
Xiaoran Yin, Yanan Cui, Richard S. Kim, Wesley R. Stiles, Seung Hun Park, Haoran Wang, Li Ma, Lin Chen, Yoonji Baek, Satoshi Kashiwagi, Kai Bao, Amy Ulumben, Takeshi Fukuda, Homan Kang, Hak Soo Choi
Summary: Image-guided surgery and drug delivery using nanotheranostic H-dots show promise in the treatment of lung cancer, providing precise tumor resection and targeted anti-cancer drug therapy with improved efficacy and reduced risks of adverse effects and drug resistance.
Review
Pharmacology & Pharmacy
Nicola Specchio, Alessandro Ferretti, Marina Trivisano, Nicola Pietrafusa, Chiara Pepi, Costanza Calabrese, Susanna Livadiotti, Alessandra Simonetti, Paolo Rossi, Paolo Curatolo, Federico Vigevano
Summary: Neuronal ceroid lipofuscinosis (NCLs) is a group of inherited neurodegenerative lysosomal storage diseases that are the most common cause of dementia in children. Various potential therapies are being developed, but there is currently a lack of study on potential treatments for CLN4, CLN9, CLN12, CLN13 or CLN14 diseases.
Review
Oncology
Katarzyna Stencel, Izabela Chmielewska, Janusz Milanowski, Rodryg Ramlau
Summary: The use of novel therapeutic drugs in lung cancer has revolutionized the diagnosis and treatment paradigms, with many new targeted therapies approved by the FDA or in clinical trials. Lung cancer remains a leading cause of cancer-related deaths globally, and specific genetic alterations indicate the suitability for targeted therapies.
Review
Oncology
Cian O'Leary, Grace Murphy, Yong Yeung, Ming Tang, Vikram Jain, Connor G. O'Leary
Summary: Non-small-cell lung cancer (NSCLC) is a common and often fatal malignancy, with Kirsten rat sarcoma virus (KRAS) mutation being a commonly mutated oncogene in NSCLC. Recently developed KRAS G12C inhibitors have overcome the therapeutic hurdle of targeting KRAS mutations. While these medications show substantial response rates in heavily pre-treated NSCLC patients, phase-3 evidence has not yet demonstrated an overall survival benefit compared to standard-of-care chemotherapy. Additionally, these medications may have a negative interaction with immunotherapies, leading to higher hepatotoxicity rates. Despite these limitations, these medications represent an important advancement in targeted and personalized oncological treatment, and future trials may provide further meaningful outcomes for guiding treatment in this patient cohort.
Review
Biochemistry & Molecular Biology
Zhenfang Du, Jinghan Sun, Yunkai Zhang, Nigaerayi Hesilaiti, Qi Xia, Heqing Cui, Na Fan, Xiaofang Xu
Summary: Oncogenic mutations in the EGFR kinase domain are well-established driver mutations in NSCLC. Targeted TKIs specifically designed for these mutations have improved treatment outcomes for patients. Structural analysis has influenced TKI development and understanding of structure will further improve patient outcomes. This review summarizes recent progress on targeted therapy strategies for EGFR-mutant NSCLC based on structure and function analysis.
Editorial Material
Cardiac & Cardiovascular Systems
Mehdi Tahiri, Anastasia Bykova, Ben Dunne, David Barth, Laura Donahoe, Thomas K. Waddell, Karen McRae, Peter Slinger, John Granton, Marc de Perrot
ANNALS OF THORACIC SURGERY
(2020)
Article
Radiology, Nuclear Medicine & Medical Imaging
Daniel Andrzej Szulc, Mohammadali Ahmadipour, Fabio Gava Aoki, Thomas K. Waddell, Golnaz Karoubi, Hai-Ling Margaret Cheng
MAGNETIC RESONANCE IN MEDICINE
(2020)
Article
Critical Care Medicine
Marcelo Cypel, Jordan J. Feld, Marcos Galasso, Rafaela V. Pinto Ribeiro, Nikki Marks, Magdalena Kuczynski, Deepali Kumar, Ilona Bahinskaya, Vanderlei S. Bagnato, Cristina Kurachi, Arthur S. Slutsky, Jonathan C. Yeung, Laura Donahoe, Marc de Perrot, Kazuhiro Yasufuku, Andrew Pierre, Matthew Binnie, Cecilia Chaparro, Tereza Martinu, Manyin Chen, Jussi Tikkanen, Chung-Wai Chow, Aman Sidhu, Thomas K. Waddell, Shaf Keshavjee, Lianne G. Singer, Atul Humar
LANCET RESPIRATORY MEDICINE
(2020)
Article
Cardiac & Cardiovascular Systems
Jonathan C. Yeung, Tiago N. Machuca, Cecilia Chaparro, Marcelo Cypel, Anne L. Stephenson, Melinda Solomon, Tomohito Saito, Matthew Binnie, Chung-Wai Chow, Hartmut Grasemann, Andrew F. Pierre, Kazuhiro Yasufuku, Marc de Perrot, Laura L. Donahoe, Jussi Tikkanen, Tereza Martinu, Thomas K. Waddell, Elizabeth Tullis, Lianne G. Singer, Shaf Keshavjee
JOURNAL OF HEART AND LUNG TRANSPLANTATION
(2020)
Article
Cardiac & Cardiovascular Systems
Khaled Ramadan, Bruno Gomes, Mauricio Pipkin, Mariola Olkowicz, Barbara Bojko, Arnaud Romeo Mbadjeu Hondjeu, Shaf Keshavjee, Thomas Waddell, Janusz Pawliszyn, Marcelo Cypel
Summary: The study aimed to determine the dose-limiting toxicity of oxaliplatin chemotherapy delivered by in vivo lung perfusion (IVLP) and developed a 72-hour porcine IVLP survival model. Results showed clinically significant lung injury at 80 mg/L oxaliplatin, and mild and subclinical lung injury at 40 mg/L. These findings will guide the initiation of a clinical trial examining IVLP delivery of oxaliplatin.
JOURNAL OF THORACIC AND CARDIOVASCULAR SURGERY
(2021)
Article
Cardiac & Cardiovascular Systems
Robert Qaqish, Yui Watanabe, Konrad Hoetzenecker, Jon Yeung, Manyin Chen, Andrew Pierre, Kazuhiro Yasufuku, Laura Donahoe, Marc de Perrot, Tom Waddell, Shaf Keshavjee, Marcelo Cypel
Summary: Short- and long-term outcomes are similar between recipients of lungs from donation after neurologic determination of death and donation after circulatory determination of death. Different intervals between withdrawal of life-sustaining therapies and cardiac arrest did not impact recipient outcomes, and the maximum acceptable duration of this interval remains to be established.
JOURNAL OF THORACIC AND CARDIOVASCULAR SURGERY
(2021)
Article
Cardiac & Cardiovascular Systems
Biniam Kidane, Sean Higgins, Dhruvin H. Hirpara, Suha Kaaki, Yu Cindy Shen, Frances Allison, Thomas K. Waddell, Gail E. Darling
Summary: Although post-esophagectomy emergency department utilization is high, the majority of visits do not convert to inpatient admission. Anastomotic leak is independently associated with higher odds of conversion to admission. Patients living in regions further away tend to utilize closer local hospitals, resulting in lower conversion rates to admission at the index hospital.
ANNALS OF THORACIC SURGERY
(2021)
Article
Cell & Tissue Engineering
Mohammadali Ahmadipour, Pascal Duchesneau, Daisuke Taniguchi, Thomas K. Waddell, Golnaz Karoubi
Summary: The study showed that cell delivery via negative pressure improved the efficiency and cell surface coverage area of recellularization of bioengineered lungs, indicating that negative pressure cell delivery is a more effective approach.
TISSUE ENGINEERING PART C-METHODS
(2021)
Article
Multidisciplinary Sciences
Hankyu Lee, Alba E. Marin-Araujo, Fabio G. Aoki, Siba Haykal, Thomas K. Waddell, Cristina H. Amon, David A. Romero, Golnaz Karoubi
Summary: This study utilized computational fluid dynamics to redesign the fluid delivery system of a trachea bioreactor and improve the perfusion cell seeding protocol to promote uniform cell deposition. The research demonstrated that low rates of rotation provide more uniform cell deposition patterns and enhance re-epithelialization of long segment tracheal grafts. Lessons learned from this study can be applied to culturing of any tissue engineered tubular scaffold.
SCIENTIFIC REPORTS
(2021)
Article
Biochemical Research Methods
Eric A. Chadwick, Takaya Suzuki, Michael G. George, David A. Romero, Cristina Amon, Thomas K. Waddell, Golnaz Karoubi, Aimy Bazylak
Summary: This work presents a methodology for non-invasive high-spatial resolution 3D X-ray micro-CT of healthy mouse lung vasculature, as well as novel techniques for removing spurious branch artefacts from the skeletonized 3D image. These methods accurately characterize the structure of mouse lung vasculature and aid in studying chronic pulmonary diseases.
PLOS COMPUTATIONAL BIOLOGY
(2021)
Review
Medicine, Research & Experimental
Jin-A Lee, Alex Cho, Elena N. Huang, Yiming Xu, Henry Quach, Jim Hu, Amy P. Wong
Summary: The discovery of the Cystic fibrosis (CF) gene in 1989 has led to significant progress in treating the disease, with the average survival age of patients with CF reaching 58 years in Canada. Recent advancements in gene therapy approaches and new research models are rekindling the search for a permanent genetic cure for all CF.
JOURNAL OF TRANSLATIONAL MEDICINE
(2021)
Article
Materials Science, Biomaterials
Ratna Varma, James Poon, Zhongfa Liao, J. Stewart Aitchison, Thomas K. Waddell, Golnaz Karoubi, Alison P. McGuigan
Summary: The study evaluated the effect of topographical cues on the organization of human tracheal epithelial cells and human induced pluripotent stem cell-derived airway progenitors, finding that cilia alignment in airway cells is influenced by topographical cues under ALI culture conditions.
BIOMATERIALS SCIENCE
(2022)
Article
Cell & Tissue Engineering
Jia Xin Jiang, Leigh Wellhauser, Onofrio Laselva, Irina Utkina, Zoltan Bozoky, Tarini Gunawardena, Zoe Ngan, Sunny Xia, Michelle Di Paola, Paul D. W. Eckford, Felix Ratjen, Theo J. Moraes, John Parkinson, Amy P. Wong, Christine E. Bear
Summary: This study introduced a new testing platform that uses patient-specific iPSCs differentiated to lung progenitor cells for high-throughput assay of CFTR channel activity. The proof-of-concept studies supported the potential use of this platform in developing therapies for rare CFTR mutations.
Review
Cell Biology
Elena N. Huang, Henry Quach, Jin-A Lee, Joshua Dierolf, Theo J. Moraes, Amy P. Wong
Summary: Cystic fibrosis is a disease caused by mutations in the CFTR protein, leading to abnormal fluid and ion transport, reduced lung function, and increased mortality rate. Although progress has been made in CF research, clinical outcomes may not be mutation-specific. Research suggests that CFTR protein plays an important role in early lung development and mutant CFTR proteins may impact CF airway disease.
FRONTIERS IN CELL AND DEVELOPMENTAL BIOLOGY
(2021)
Letter
Cardiac & Cardiovascular Systems
Laura L. Donahoe, Tatsuya Kato, Andrew Healey, Thomas K. Waddell, Jodie Heffren, Caitlin Mills, Maureen Meade, Diana Hallett, Shaf Keshavjee, Marcelo Cypel
JOURNAL OF HEART AND LUNG TRANSPLANTATION
(2021)